Expression of tissue factor pathway inhibitor 2 inversely correlates during the progression of human gliomas

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Protease inhibitors are crucial in physiological and pathological processes, including tumor invasion.
• Tissue factor pathway inhibitor (TFPI)-2 is a Kunitz-type serine protease inhibitor with known inhibitory activity against several proteases.
• The role of TFPI-2 in human gliomas, a type of brain tumor, has not been fully elucidated.

Purpose of the Study:

• To investigate the expression levels of TFPI-2 in different grades of human glioma cell lines and tumor tissues.
• To determine the correlation between TFPI-2 levels and glioma malignancy.
• To assess the effect of TFPI-2 on glioma cell invasiveness.

Main Methods:

• Western blotting and Northern blotting were used to measure TFPI-2 protein and mRNA levels in glioma cell lines and tissues.
• In situ hybridization was employed to localize TFPI-2 mRNA expression in normal brain and glioma tissues.
• A Matrigel assay was performed to evaluate the impact of recombinant TFPI-2 on glioblastoma cell invasion.

Main Results:

• TFPI-2 protein and mRNA levels were highest in low-grade glioma cells and decreased with increasing malignancy, being undetectable in high-grade glioma cells.
• Normal brain tissue exhibited the highest TFPI-2 protein levels, followed by low-grade gliomas and anaplastic astrocytomas, with undetectable levels in glioblastomas.
• TFPI-2 mRNA was predominantly found in neurons in normal brain tissue, with lower expression in glial and endothelial cells, and minimal to no expression in glioma tissues.
• Recombinant TFPI-2 significantly inhibited the invasiveness of glioblastoma cells in a dose-dependent manner in vitro.

Conclusions:

• TFPI-2 expression is inversely correlated with the grade of human gliomas.
• TFPI-2 may play a suppressive role in glioma cell invasion.
• These findings suggest TFPI-2 as a potential therapeutic target for gliomas.